MEDICINE DETAILS
Poteligeo
Active ingredient: Mogamulizumab
Neutral reference profile for an independent medicine-access consultancy enquiry about Poteligeo (Mogamulizumab). No medicine is offered for sale.
NEXT STEP
Choose the strength and pack
No ready-made options were found for this medicine. You can type the details in the form.
Continue to the form→✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Poteligeo used for?
Poteligeo (mogamulizumab) is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody indicated to treat adults with mycosis fungoides (MF) or Sézary syndrome (SS) – two cancers of blood cells that affect mainly the skin. It is used in patients who had previous systemic (whole-body) treatment, and whose cancer didn’t get better, or got better but came back.
It is available in vial form, each containing 20 mg/5 ml (4 mg/ml) mogamulizumab.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Poteligeo identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
No ready-made option can be shown.
Do not guess a missing strength or pack; use the details on the prescription and medicine box.
OFFICIAL SOURCES
Check the Poteligeo record at an official source.
Search for “Poteligeo” or “Mogamulizumab”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Poteligeo.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Poteligeo
01What is Poteligeo?＋
This directory record associates the brand name Poteligeo with the active ingredient Mogamulizumab. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Poteligeo strengths and packs are recorded?＋
No ready-made strength and pack option can currently be shown from the catalogue record. Do not guess missing details; use the prescription and medicine box.
03Who manufactures Poteligeo?＋
No organisation name can currently be shown confidently from the catalogue record. Verify the manufacturer or marketing-authorisation holder on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Poteligeo?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Poteligeo, payment request, stock guarantee or binding offer.
06Can I buy Poteligeo from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.